Head to Head Contrast: Blueprint Medicines (BPMC) vs. Its Peers

Blueprint Medicines (NASDAQ: BPMC) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Blueprint Medicines to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Blueprint Medicines and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Blueprint Medicines $27.77 million -$72.49 million -19.75
Blueprint Medicines Competitors $217.29 million -$39.39 million -71.18

Blueprint Medicines’ competitors have higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

91.4% of Blueprint Medicines shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 3.4% of Blueprint Medicines shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Blueprint Medicines and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines 0 0 9 0 3.00
Blueprint Medicines Competitors 530 2393 6571 123 2.65

Blueprint Medicines presently has a consensus target price of $75.13, indicating a potential upside of 11.54%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.39%. Given Blueprint Medicines’ competitors higher possible upside, analysts clearly believe Blueprint Medicines has less favorable growth aspects than its competitors.

Profitability

This table compares Blueprint Medicines and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines -437.83% -43.11% -34.38%
Blueprint Medicines Competitors -3,356.81% -100.36% -39.83%

Volatility and Risk

Blueprint Medicines has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Blueprint Medicines’ competitors have a beta of 1.58, meaning that their average share price is 58% more volatile than the S&P 500.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.